Cardiologia

Diretriz NICE | Insuficiência cardíaca aguda: diagnóstico e tratamento.

17 Dez, 2021 | 12:16h

Acute heart failure: diagnosis and management – National Institute for Health and Care Excellence

Conteúdo relacionado: #ESCCongress – 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – SGLT2 inhibitors are now recommended for patients with heart failure with reduced ejection fraction regardless of the presence of diabetes.

Diretriz | Prevenção, diagnóstico e tratamento da mediastinite pós-cirúrgica em adultos.

17 Dez, 2021 | 12:11h

Prevention, Diagnosis and Management of Post-Surgical Mediastinitis in Adults Consensus Guidelines of the Spanish Society of Cardiovascular Infections (SEICAV), the Spanish Society of Thoracic and Cardiovascular Surgery (SECTCV) and the Biomedical Research Centre Network for Respiratory Diseases (CIBERES) – Journal of Clinical Medicine

Perspectiva | Introdução à nefrocardiologia.

16 Dez, 2021 | 12:39h

Introducing Nephrocardiology – Clinical Journal of the American Society of Nephrology

Riscos de miocardite, pericardite e arritmias cardíacas associadas à vacinação contra COVID-19 vs. infecção por SARS-CoV-2.

15 Dez, 2021 | 12:45h

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection – Nature Medicine

Comunicado de imprensa: COVID-19 infection, more likely than vaccines, to cause rare cardiovascular complications – University of Oxford

Comentários no Twitter

Hugely important work from @JuliaHCox and colleagues:

In people <40, Pfizer carries a much lower risk of myocarditis than either Moderna **or SARS-CoV-2 infection** (annotations added)https://t.co/wqRts3ALqy pic.twitter.com/fnn1T39h1b

— David Juurlink (@DavidJuurlink) December 14, 2021

A case series published in @NatureMedicine shows an increased risk of myocarditis after receiving the Astra-Zeneca-Oxford, Pfizer-BioNTech and the Moderna COVID-19 vaccines, but SARS-CoV-2 infection carried a greater risk of myocarditis. https://t.co/6y7pZlJN70 pic.twitter.com/cBlKz9sUkg

— Nature Portfolio (@NaturePortfolio) December 14, 2021

Just published @NatureMedicine
The most comprehensive assessment of the rare events of myocarditis, pericarditis, arrhythmias after COVID and AZ, mRNA vaccineshttps://t.co/0bEdMJSLXg pic.twitter.com/eC5JOx0CmG

— Eric Topol (@EricTopol) December 14, 2021

Alta hospitalar precoce é factível após intervenção coronariana percutânea em pacientes com infarto do miocárdio com elevação do segmento ST.

15 Dez, 2021 | 12:26h

Early Hospital Discharge Following PCI for Patients With STEMI – Journal of the American College of Cardiology (link para o resumo – $ para o texto completo)

Estudo randomizado sobre o uso de metoprolol em pacientes com cardiomiopatia hipertrófica obstrutiva.

15 Dez, 2021 | 12:25h

Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy – Journal of the American College of Cardiology (link para o resumo – $ para o texto completo)

Comentário: The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy – TEMPO – American College of Cardiology

Recomendação de consenso | Exames de imagem não invasivos em síndromes coronarianas.

14 Dez, 2021 | 16:07h

Non-invasive imaging in coronary syndromes: recommendations of the European Association of Cardiovascular Imaging and the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance – European Heart Journal – Cardiovascular Imaging

Podcast | Zero tensão para a hipertensão do paciente internado.

14 Dez, 2021 | 15:58h

#310 No Tension About Inpatient Hypertension with Dr. Noble Maleque – The Curbsiders

Análise agrupada de estudos randomizados sobre o efeito da empagliflozina em pacientes com insuficiência cardíaca dentro do espectro de fração de ejeção (FE) ventricular esquerda mostrou que os efeitos foram clinicamente significativos e similares em pacientes com FE abaixo de 65%, porém atenuados em pacientes com FE acima de 65%.

13 Dez, 2021 | 11:28h

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction – European Heart Journal

Comentário no Twitter

Effect of empagliflozin on heart failure hospitalizations: news from the pooled analysis on both the EMPEROR-Reduced and EMPEROR-Preserved trials! #empaglifozin #heart #failure #hospitalization #ehj #cardiotwitter @escardio @ESC_Journals https://t.co/W6FuYbwVzx pic.twitter.com/5qLXDVaC89

— EHJ Editor-in-Chief (@ehj_ed) December 11, 2021

Diretriz ACC/AHA/SCAI 2021 para revascularização da artéria coronária.

10 Dez, 2021 | 11:24h

Foco da diretriz: 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization

Diretriz completa: 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Resumo executivo: 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization

Comunicado de imprensa: Coronary Revascularization the Focus of New ACC/AHA Clinical Guideline

Conjunto de slides da ACC/AHA: 2021 ACC/AHA/SCAI Guidelines for Coronary Artery Revascularization

Principais itens a saber: 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization

Perspectivas principais: ACC/AHA/SCAI Coronary Revascularization Guideline